






| JOB OFFER | | | | | | | | | |
|--|---|----------------|---|--|---|--|--|--|--|
| REFERENCE | | OPENING DATE | | DATE | DEADLINE | | | | |
| 2021.354 | | 10/05/202 | |)24 | 19/05/2024 | | | | |
| PROFILE REQUIREMENTS | | | | | | | | | |
| EXCLUSIVE REQUIREMENTS: (1) | | | | | | | | | |
| ACADEMIC DEGREE | Bachelor and Master Degree in Biosciences related field and/or Biochemistry. | | | | | | | | |
| VALUED MERITS /SKYLLS | | | | | | | | | |
| EXPERIENCE | In laboratory techniques related to cell biology, flow cytometry, molecular and | | | | | | | | |
| OTHERS REQUIREMENTS | proteomic biology, in vivo studies. • Average grade higher than 8 | | | | | | | | |
| LANGUAGES | • English | | | | | | | | |
| CONTRACT INFORMATION | | | | | | | | | |
| TYPE OF CONTRACT | Т | | D INCORPORATION DATE | | JOB STATUS | | | | |
| Indefinite in accordance with Article 23 Bis of Law 14/2011, of June 1, 2011, on Science, Technology and Innovation. | | September 2024 | | 2024 | Full | | | | |
| ANNUAL GROSS SALARY DURATION OF THE CONTRACT | | | | | | | | | |
| 26,066.88, without prejudice to the basic update established in state legislation for 2024. | | | | Indefinite, linked to the duration of the project and economic availability based on RDL8/2022 | | | | | |
| WORK LOCATIONS | | | UNIT/DEPARTMENT | | | | | | |
| IDIVAL | | | Hematologic Neoplasms and Hematopoietic Progenitor Transplantation | | | | | | |
| | | JOB DI | ETAILS | | | | | | |
| | | OFFER DES | CRIPTI | ON | | | | | |
| | R | esearch supp | ort tech | nician | | | | | |
| | | FUNC | TIONS | | | | | | |
| The project to be developed if flow cytometry, bioinformation | | | | | reas such as molecular biology, national projects. | | | | |
| PRINCIPAL INVESTIGATOR RESPONSABLE | / RE | ESEARCH GROUP | | RESEARCH PROJECT | | | | | |
| Dr. Enrique M. Ocio | and Proger | Hemato | Neoplasms ematopoietic ion bortezomib, dexamethasone ciltacabtagene antigen recept directed again lenalidomide a followed by dexamethasone diagnosed patie for whom | | phase III study comparing lenalidomide, and ne (VRd) followed by e autoleucel, a chimeric eptor T-cell (T-CAR) therapy ainst BCMA vs. bortezomib, and dexamethasone (VRd) by lenalidomide and ne (Rd) therapy in newly atients with multiple myeloma hematopoietic stem cell on is not planned as initial | | | | |

Av. Cardenal Herrera Oria s/n 39011 Santander - España

www.idival.org Tel. +34 942 31 55 15 Fundación Instituto de Investigación Marqués de Valdecilla CIF: G 39788773

Translated with DeepL.com (free version)



DIRECCIÓN DE VALIDACIÓN : https://portafirmas.redsara.es/pf/valida

FIRMANTE(1): FRANCISCO GALO PERALTA FERNANDEZ | FECHA: 09/05/2024 12:41 | Sin acción específica

RECRUITMENT INFORMATION









| SELECTION PROCESS STAGES (2) | EMPLOYMENT EXCHANGE |
|---|---------------------|
| 1. Admission of applications 2. Competition phase. 3.Interview phase: Minimum score for this phase: 40 4.Report of the Selection Board 5.Resolution | NOT |

SELECTION BOARD

- Enrique M. Ocio, Project's Main Researcher
- Patricia Maiso, IDIVAL Researcher
- Maria José Marín Vidalled, IDIVAL Technology Services Coordinator

| VALUATION OF MERITS | | | | | | | | |
|--|--------------|-------------------|------------|----|--|--|--|--|
| MERITS | EVALUATION | SCOR | MAXIMUM | | | | | |
| Knowledge of techniques related to molecular biology | Curricular | Merit fulfillment | YES/NO | 30 | | | | |
| Average grade higher than 8 | Acreditation | Merit fulfillment | YES/NO | 20 | | | | |
| English | Acreditation | Level | B2:5 C1:10 | 10 | | | | |
| FINAL SCORE | | | | | | | | |
| MAXIMUM TOTAL SCORE BY MERITS | | | | | | | | |
| MAXIMUM TOTAL SCORE IN INTERVIEW | | | | | | | | |
| MAXIMUM TOTAL SCORE | | | | | | | | |

(1) Not subsanable

(2) See duration of each phase in the document "Selection Process"

In compliance with the provisions of Article 11 of Organic Law 3/2018, you are informed that the person responsible for the processing of your personal data is the MARQUES DE VALDECILLA INSTITUTE OF INVESTIGATION FOUNDATION (IDIVAL), your data will be treated in order to be treated to the extent that they were necessary or convenient for the development of the legal relationship established between the parties. You can exercise your rights of access, rectification, deletion, opposition, portability or limitation of the treatment, by contacting the IDIVAL FOUNDATION at the following address: AVDA. CARDENAL HERRERA ORIA, S / N 39007, SANTANDER. More information at www.idival.org/es/Politica-de-Privacidad

Santander a fecha de la firma electrónica

Fdo. Francisco Galo Peralta Fernández



www.idival.org Tel. +34 942 31 55 15 Fundación Instituto de Investigación Marqués de Valdecilla CIF: G 39788773

